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Abstract
Background: Several agents are available to treat osteoporosis while addressing patient-specific medical needs. Individuals’
residual risk to severe fracture may require changes in treatment strategy. Data at osseous cellular and microstructural levels
due to a therapy switch between agents with different modes of action are rare. Our study on a series of five consecutively
taken bone biopsies from an osteoporotic individual over a six-year period analyzes changes in cellular characteristics, bone
microstructure and mineralization caused by a therapy switch from an antiresorptive (bisphosphonate) to a dual action
bone agent (strontium ranelate).
Methodology/Principal Findings: Biopsies were progressively taken from the iliac crest of a female patient. Four biopsies
were taken during bisphosphonate therapy and one biopsy was taken after one year of strontium ranelate (SR) treatment.
Furthermore, serum bone markers and dual x-ray absorptiometry measurements were acquired. Undecalcified histology
was used to assess osteoid parameters and bone turnover. Structural indices and degree of mineralization were determined
using microcomputed tomography, quantitative backscattered electron imaging, and combined energy dispersive x-ray/m-
x-ray-fluorescence microanalysis.
Conclusions/Significance: Microstructural data revealed a notable increase in bone volume fraction after one year of SR
treatment compared to the bisphosphonate treatment period. Indices of connectivity density, structure model index and
trabecular bone pattern factor were predominantly enhanced indicating that the architectural transformation from
trabecular rods to plates was responsible for the bone volume increase and less due to changes in trabecular thickness and
number. Administration of SR following bisphosphonates led to a maintained mineralization profile with an uptake of
strontium on the bone surface level. Reactivated osteoclasts designed tunneling, hook-like intratrabecular resorption sites.
The appearance of tunneling resorption lacunae and the formation of both mini-modeling units and osteon-like structures
within increased plate-like cancellous bone mass provides additional information on the mechanisms of strontium ranelate
following bisphosphonate treatment, which may deserve special attention when monitoring a treatment switch.
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Introduction
Currently, several agents are available to address patients’
specific medical needs when treating osteoporosis. Anti-resorptive
drugs with various modes of action (e.g., bisphosphonates (BP),
hormone replacement therapy, selective estrogen-receptor modu-
lators and RANK ligand (RANKL) inhibitors slow the progression
of bone loss [1,2,3,4], whereas other agents stimulate bone
formation (e.g., parathyroid hormone fragments) to support
increases in bone mass [4,5,6]. Strontium Ranelate (SR) is
promoted as a treatment for postmenopausal osteoporosis with a
dual mechanism on bone remodeling: inhibition of osteoclastic
resorption and activation of osteoblastic apposition. Its antifracture
efficacy in the treatment of postmenopausal osteoporosis has been
shown in previous clinical trials [7,8,9,10], where Bone Mineral
Density (BMD) increases under SR treatment were measured with
Dual X-Ray Absorptiometry (DXA). The observed BMD gain is
partially due to SR deposition in bone [9,10,11]. To what extent
this mechanism occurs in humans as well as how it has to be
considered during long-term treatment is mostly based on
theoretical models and is still under investigation [12,13,14]. It
has been shown that SR is incorporated in a dose-dependent
manner into new bone (and less into pre-existing old bone) without
detrimental effects on bone mineralization [11,15,16]. Only a few
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in vivo microstructural studies or human (histological) data have
been reported about the desired effect of a positively influenced
uncoupling of bone formation and bone resorption on cohorts
following long-term BP treatment [11,17]. Focusing on the
previously mentioned issues, this study presents the time-associated
development of cellular characteristics, serum markers, bone
microstructure and mineralization caused by a therapy switch
from an antiresorptive (bisphosphonate) to a dual action bone
agent (strontium ranelate) in five progressively taken bone biopsies
from an osteoporotic individual over a six-year period.
Materials and Methods
Bone biopsies were obtained from the Hamburg Bone Register
at the University Medical Center Hamburg-Eppendorf. The
Hamburg Bone Register is a collection of diseased human bone
samples representing patients covering various bone pathologies;
the samples are prepared and archived in an undecalcified state.
Documentation is available for each biopsy regarding the details of
the patients, including their history, treatment course, and clinical
complications. This resource enabled tracking and analysis of the
following case of osteoporosis in a female patient over a six-year
time period. The patient characteristics for this study are as
follows. The patient was postmenopausal, 75 years old and had
multiple vertebral fractures (Th 6–8; LS 2–4) before initiating the
BP treatment. During the BP treatment, new or progressive
vertebral fractures were detected with an additional reduction in
height accompanied by an unchanged low BMD; thus, treatment
was switched from BP to SR. The study was approved by the
institutional review boards of the University of California, Berkeley
& San Francisco and IDG Immanuel Diakonie Group Berlin/
Brandenburg. Informed written consent was given by the patient
for the study and publication of the data. Five consecutive iliac
crest biopsies were obtained from the patient over a period of six
years; at the same time as the biopsies, the associated hip T-Scores
(comparison of the patient’s BMD value to the mean BMD of the
young adult healthy population) [11] and serum biomarkers were
determined. Both the presence and concentration of type I
collagen’s crosslink peptide sequence were measured by the
biomarker for carboxy-terminal collagen crosslinks (CTX). The
portion of this peptide sequence that is cleaved by osteoclasts
during bone resorption provides bone turnover information,
where its serum levels are a proportional measure of osteoclastic
activity [18]. Serum bone-specific alkaline phosphatase (bAP) was
measured as a biochemical indicator of bone turnover. The bone-
specific isoform of alkaline phosphatase is a tetrameric glycopro-
tein found on the surface of osteoblasts and can be used as an
index of active bone formation [19]. Calcium and phosphorus
blood samples were analyzed to differentiate between osteoporosis
and other diseases associated with fracture risk and low bone
mineral density [20].
All of the bone biopsies were performed at the same clinic by
one of the authors (JS, Immanuel-Hospital Berlin-Wannsee,
Berlin, Germany), who has experience with over 5000 iliac crest
biopsies. All of the biopsies were taken during the BP and SR
treatment periods (Fig. 1), see the timeline in figure 1. The side of
the pelvis that the biopsy was extracted from was alternated at
each visit; biopsies taken from the same side were extracted at a
similar site but at a different biopsy angle. Therefore, biopsies
1,3,5 and biopsies 2,4 were taken in an alternating caudocranial or
craniocaudal direction to avoid regional overlaps and possible
interference from regional acceleratory phenomenon (RAP) or
other bone healing effects [6,21]. JS used an 8-gauge Jamshidi
needle with an inner diameter of 3 mm to obtain the biopsies. The
biopsies meet the standard required for histomorphometry
because the length of the biopsies averages 2 cm (0.79 in.). Thus,
the bone volume of Jamshidi biopsies for histomorphometry
equates to the bone volume of transiliacal Bordier biopsies without
the limiting factor of bilateral subcortical bone heterogeneity
[6,11].
Micro-computed Tomography (mCT)
Undecalcified and polymethylmethacrylate (PMMA) embedded
biopsies were scanned with a micro-computed tomography system
(mCT 40, Scanco Medical AG, Basserdorf, Switzerland) with a 12-
mm isotropic nominal resolution. Application of the threshold
algorithm is based on previous studies and has been described in
detail [22,23]. The bone volume fraction (BV/TV), trabecular
thickness (Tb.Th.), trabecular separation (Tb.Sp.), trabecular
number (Tb.N.), connectivity density (Conn.D), structure model
index (SMI) and trabecular bone pattern factor (TBPf) were
measured from the segmented images as described elsewhere [24].
Figure 1. Timeline of treatment and biopsy obtainment. We investigated 5 serial iliac crest biopsies from a 75-year-old female patient over a
period of 6 years. The patient was diagnosed with osteoporosis with multiple vertebral fractures and was first treated with bisphosphonates (BP) for
26 months (biopsy 1). The BP treatment was halted for 12 months until a second biopsy was obtained (biopsy 2). The BP treatment was then
continued and another biopsy was taken after 13 months (biopsy 3). The antiresorptive therapy was stopped after an additional 51 months of
treatment and another biopsy was taken (biopsy 4). Next, strontium ranelate was administered for 12 months (2g/d) in total before another iliac crest
biopsy was conducted. BP and SR were administered according to the manufacturer’s instructions and the patient additionally received a Vitamin D3
metabolite during osteoporosis treatment.
doi:10.1371/journal.pone.0023638.g001
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Conn.D, SMI and TBPf are closely related to each other and
provide information about the characteristics of the cancellous
bone structure. Calculation of the Euler characteristics can be
applied to networks to provide information regarding the number
of connected entities within the structure [25,26]. In networks of
cancellous bone, the connectivity density (Conn.D) can be
calculated by dividing the connectivity estimate by the volume of
the sample. Basically, Conn.D provides an estimation of the
number of trabecular connections per unit volume [25,26]. The
structure model index (SMI) determines the geometry of the
intertrabecular network. It is based on the change in surface area
with an infinitesimal increase in volume. Quantification of the
SMI gives an impression of whether the trabecular structure
consists of a plate-like (SMI < 0) or rod-like (SMI < 3)
configuration [26,27]. In cortical bone, the SMI may shift towards
negative values if many concave surfaces are present [27]. The
TBPf describes the ratio of intertrabecular connectivity, which was
first developed to analyze histological sections in 2D [28]. The
concept of TBPf is based on varying values for the convexity and/
or concavity of a structure. Due to dilation, there will always be
increases in bone area but increases in bone perimeter only occur
with convex surfaces. Trabecular bone with many concave
structures has a negative TBPf, whereas many convex structures
results in a positive value (osteopenia/osteoporosis) [28]. A low
TBPf value reflects a cancellous morphology that has adapted
from a rod-like configuration to a plate-like configuration.
Excellent correlation has been reported between the SMI and
2D-TBPf [28,29]. The bone tissue density was determined from
the original mCT grayscale images. The binary image map from
the segmentation step was eroded by two voxels to remove partial
volume components and to mask the grayscale data. The mean
linear attenuation was calculated as the sum of the masked image
divided by the number of bone voxels in the eroded mask. This
value was converted to mineral density (MD) in mg HA/cm3
based on a phantom-derived linear calibration [22,30].
Undecalcified histology
Bone biopsies were sectioned to a 4-mm thickness and stained
with Goldner-Masson, Giemsa and Tartrate Resistant Acid
Phosphatase (TRAP). Osseous cells and osteoid indices were
assessed quantitatively in accordance with the guidelines of the
American Society of Bone and Mineral Research [31,32] using
histomorphometry software OSTEO II (Bioquant, Nashville, TN,
USA). The ratio of the osteoid surface to the bone surface (OS/
BS,%), the ratio of the osteoblast surface to the bone surface
(Ob.S/BS,%), the ratio of the number of osteoblasts to the bone
surface (N.Ob/BS, #/mm) and the ratio of the number of
osteoclasts to the bone surface (N.Oc/BS, #/mm) were
determined. Bone turnover was classified by analyzing serum
markers (bAP and CTX) [33,34,35,36,37,38,39] and osteoid
indices [40,41,42,43,44], which were compared to reference values
from the literature for naı¨ve and treated patients. Furthermore,
visible bone remodeling units were evaluated [45] as an additional
supportive measurement indicating bone turnover information
and were based on the following histological criteria. The total
number of osteoblasts and osteoclasts were counted at individual
bone remodeling units (magnification 40x) and divided by the total
number of assessed fields of view (approx. 4–6). ‘Low turnover’ is
attributed to bone tissue under low endosteal remodeling showing
,1 bone remodeling unit with cubic-shaped osteoblasts and a
maximum of one osteoclast per field of view (magnification 40x) in
the underlying histological section. ‘Normal turnover’ is attributed to
bone tissue with maintained endosteal remodeling showing 1–2
bone remodeling units with cubic-shaped osteoblasts and 2–4
single osteoclasts per field of view (magnification 40x). ‘High
turnover’ is attributed to bone tissue with both increased endosteal
remodeling and osteoclastic resorption showing .2 bone remod-
eling units with prominent seams of osteoblasts and .4 groups of
osteoclasts per field of view (magnification 40x) in the underlying
histological section. Polarized light was used to observe collagen
birefringence and lamellar orientation [46,47].
Bone mineral density distribution and microanalysis
The bone mineral density distribution was measured on plastic-
embedded cross-sections of iliac crest biopsies with coplanar,
polished and carbon-coated surfaces using quantitative backscat-
tered electron imaging (qBEI) [11,48,49,50]. The scanning
electron microscope (LEO 435 VP, LEO Electron Microscopy
Ltd., Cambridge, England) was operated at 15 kV and 665 pA at a
constant working distance (BSE Detector, Type 202, K.E.
Developments Ltd., Cambridge, England). The pixel size was 3
ı`m, as recommended by Roschger et al. [50]. Synthetic
hydroxyapatite (HA) samples were used to create a calibration
curve. These HA samples (DOT Medical Solutions, Rostock,
Germany) contained different Ca/P ratios, which were deter-
mined with energy dispersive X-ray analysis (DX-4, EDAX,
Mahwah, NJ) and qBEI. A highly linear relationship between the
gray values of backscattered signal intensities and the calcium
content of each sample has been reported previously by other
authors [49,51], enabling calibration of the method. The
generated mineralization profile (gray value histogram) reflects
the degree of mineralization in the cross-sectioned bone.
Strontium deposition in mineralized bone tissue was measured
using mXRF (Micro-X-ray Fluorescence Analysis; IMOXS, IFG,
Germany) in combination with EDX (Energy Dispersive X-ray
Analysis); EDAX DX-4, USA). An XRF-module with capillary
zoom optics enables x-ray fluorescence analysis in the SEM with a
high sensitivity. The advantage of this method is the high spatial
resolution [11,52]. The detection limit ranges between 1 and 0.01
weight percent (wt%) due to electron-induced Bremsstrahlung
background. The strontium (Sr) content in the bone biopsies was
evaluated in wt% via software that enabled combined EDX/
mXRF quantification (IMOXS Quant 2.10, IFG, Berlin, Ger-
many).
Results
Clinical data
C-terminal cross-linking telopeptides of type I collagen (CTX)
were consistently at very low levels (43–95 pg/ml) under
antiresorptive therapy (Fig. 2A) in comparison to the range of
mean CTX values (331–562 pg/ml) in the literature for naı¨ve
postmenopausal women [33,38]; after antiresorptive treatment,
the CTX values may range at approx. a quarter of the baseline
[34,35]. CTX rose to moderate levels (255 pg/ml) [33,38] after
the SR treatment was initiated (Fig. 2A). At the same time, the
bone specific alkaline phosphatase (bAP) level rose from 13.5 to
21.7 mg/l (Fig. 2B) in comparison to the range of mean bAP values
(13.6–17.3 mg/l) from the literature for naı¨ve postmenopausal
woman [33,36], which may decrease by approx. 45% during
bisphosphonate treatment [37,39]. Calcium/phosphorus levels
were in the normal range [53]. During BP treatment, new or
progressive vertebral fractures (Th 7, 8, 12; LS 2, 3) were
determined with an additional 6-cm reduction in height. DXA
measurements showed only minor changes in the BMD at the
femoral neck following BP treatment and following SR treatment
(Fig. 2C). The T-score at the lumbar spine increased by 0.3 T-
score points to 23.5, but its interpretation was very limited due to
Trabecular Reorganization after Treatment Switch
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multiple fractures. No DXA density correction factor related to the
period of strontium ranelate treatment was applied.
mCT tomography
The bone volume fraction, structural parameters and bone
tissue density data from all five biopsies collected by mCT are
shown in figure 3. In comparison with all biopsies after BP
treatment (Biopsy 1, 2, 3 and 4), the trabecular architecture after
SR administration (Biopsy 5) changed notably (Fig. 3A–E). The
trabecular architecture in biopsies 1–4 (Fig. 3A–D) consisted
mainly of thin rod-like structures or plates connected by very thin
rods. In biopsy 5 (Fig. 3E), a high increase in BV/TV (22% vs.
6%) along with an increase in Tb.Th. (0.2 vs. 0.17) was observed
(Fig. 3F,G). The 3D reconstruction shows thick, plate-like
structures that seemed to be connected mainly by plates and a
small number of rods, which represents a small reduction in
trabecular number and a very high connectivity density (Conn.D.:
8.2) (Fig. 3H–J). The SMI (Structural Model Index) and trabecular
bone pattern factor (TBPf) presented had improved values (SMI;
20,81 vs. 5,49 and TBPf; 21,15 vs. 2,27) (Fig. 3K,L). Recon-
struction of biopsies 1,4 and 5 showed small microcallus
formations as a result of biomechanical instability and thus
trabecular fracture (Fig. 3A,D,E). The mean density measured by
mCT in milligrams of hydroxyapatite per bone tissue volume had
already reached a high value of 1126 mg HA/cm3 after 26 months
of BP treatment (Biopsy 1), dropped after cessation of antiresorp-
tive treatment to 1085 mgHA/cm3 (Biopsy 2) and increased again
to 1144 mgHA/cm3 under a status of reduced bone turnover
(Biopsy 4). The mean density after 12 months SR remained almost
unchanged at 1133 mg HA/cm3 (Biopsy 5) during a normal bone
turnover situation (Fig. 3M).
In contrast to flat, reticulate, perforating resorption cavities in
biopsies during BP treatment (Fig. 3A–D), multiple deep, hook-like
[15] resorption patterns were visible on the surface and on sections
of biopsy 5 (Fig. 3E,4A). Small humps of endosteal bone
(peritrabecular surfaces) were detected in mCT reconstructions
and histology (Fig. 4B–E). Peak densities measured in the
cancellous bone ranged between 1200–1300 mg HA/cm3
(Fig. 4D). A maximum value of 1400–1500 mg HA/cm3 was
detected in a microcallus formation in biopsy 5 (Fig. 3E). The
lowest values in recently mineralized modeling sites ranged
between 650 to 850 mg HA/cm3 (Fig. 4D).
Undecalcified histology
Following 12 months of SR administration, individual trabec-
ulae were thicker as expected in healthy women of that age group
[54,55] and presented a somewhat irregular connectivity
(Fig. 4B,E). Woven bone was not observed in any of the biopsies.
However, following strontium ranelate treatment, several thick
trabeculae had deep intratrabecular resorption cavities filled with
fibrovascular tissue (Fig. 4B). Osteon-like structures in the
trabecular bone were seen frequently (Fig. 4B). Seams of osteoid
only partially covered with osteoblasts were occasionally present in
the form of endosteal humps (Fig. 4C,E) on top of straight cement
lines, which suggests that endosteal apposition took place without
prior resorption (modeling). A genuine fibro-osteoclasia was not
visible. Remodeling indices (Fig. 4G–J) determined by 2D
histomorphometry (Fig. 5A) provide histological bone turnover
information. Normal mean values for OS/BS have been reported
between 9.51% and 35% for female cohorts [40,41,42], whereas a
bisphosphonate treatment regime is known to decrease OS/BS
mean values to within a range of 1.02% to 3%, in accordance with
low bone turnover [43,44] (Fig 4G).
Figure 2. Clinical data. A) C-terminal cross-linking telopeptides of
type I collagen (CTX) showed very low levels under antiresorptive
therapy and rose to normal levels after SR treatment was initiated. B)
The bone specific alkaline phosphatase (bAP) level varied under BP
treatment from 25.9 to 13.5 mg/l. After the treatment was switched to
SR, the bAP level rose again to 21.7 mg/l. C) DXA measurements showed
only marginal changes in bone mineral density at the femoral neck
following both the BP and SR treatments.
doi:10.1371/journal.pone.0023638.g002
Trabecular Reorganization after Treatment Switch
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Figure 3. mCT reconstructions of biopsies and structural indices. A) mCT-3D reconstruction of the complete bone core (biopsy 1). Rod-like
structures with a microcallus formation (*R) are evident in the trabecular architecture. Some rods are likely to be perforated (R). B) mCT
reconstruction of biopsy 2. Bone core with a combination of plate- and rod-like architecture. Note the thinning of the connecting rods (R) and
reticulate perforation sites on a plate (*R). C) mCT reconstruction of biopsy 3. The trabecular architecture of this bone core presents an irregular
composition of fine rod-like elements with some small plates. Several dead-ending rods are visible (R). D) mCT reconstruction of biopsy 4. The
trabecular architecture in this iliac crest sample is almost completely deteriorated. Another trabecular fracture of a rod leading to microcallus
formation is visible (R). Microcallus formations are bulky nodes with an irregular oftentimes clefted structure. E) mCT reconstruction of the biopsy
after one year of SR treatment showing thick plate-like structures containing multiple intratrabecular ‘tunnels’. Although a very dense architecture is
evident in the structure, big gaps of lost connectivity are also visible. Bulky microcallus formation (R). F–L) Changes in the trabecular network
emphasized by structural indices evaluated through assessment of 3D mCT reconstructions. The dots represent mean values, and the error bars
represent standard deviations of the mean. M) Mean density measured by mCT showed already high values during BP treatment that can be traced
back to low bone turnover. The mean density after 12 months of SR remained almost unchanged suggesting maintained mineralization during a
normal bone turnover situation.
doi:10.1371/journal.pone.0023638.g003
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PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23638
Bone mineral density distribution and microanalysis
Backscattered signal intensities reflected a maintained mean
hard tissue mineralization (Fig. 5B). Combined EDX/mXRF
microanalysis revealed a deposition of 1.63 Wt% strontium in the
mineralized tissue after SR treatment (Fig. 5C,D). Lower
mineralized regions (dark gray values) showed increased strontium
content and appeared more commonly around osteon-like
structures (Fig. 5B,C) but were also present in modeling sites on
endosteal surfaces (peritrabecular surfaces) (Fig. 5C). Before
treatment, the strontium content ranged at the detection limit of
the method.
Discussion
One year of SR administration following long-term bisphos-
phonate treatment revealed a notable increase in bone volume
fraction. This structural change reflected more of a transformation
of trabecular rods to plates than an increase in trabecular thickness
Figure 4. Reorganization pattern, mCT mean density and 2D histomorphometry. A) mCT reconstruction of biopsy 5. Note the coarse
structure with surface irregularities and the occurrence of an intratrabecular ‘tunnel’. The area with the dark-colored background demonstrates the
2D section plane as it can be seen on the histology section in panel B. B) Congruent histology section following the mCT slice in panel A. Note the
irregular trabecular structure with varying trabecular diameter. The thickened trabecular architecture indicates intratrabecular resorption sites filled
with fibrovascular tissue (mineralized bone = light purple; Giemsa, 40x). C) A high magnification of the mCT reconstruction of biopsy 5 indicates the
irregular trabecular surface with multiple hook-like, tunneling and sometimes perforating resorption lacunae. Virtual serial sections can show that all
intratrabecular ‘tunnels’ are connected at some point and have openings to the trabecular surface. Small humps due to bone formation (mini-
modeling) arise from the trabecular surface (R). D) Axial mCT section of biopsy 5: Distribution of local mineral densities (mg HA/cm3) represented by
different gray levels. Due to bone formation, a low mineral content is detected in the proximity of new osteons, whereas the interstitial regions show
a higher mineral content due to an older tissue age. E) Two (re-)modeling sites with distinct osteoid seems are visible. The osteoid seam on the
trabecular surface at the bottom (white arrow) is covered with some cubic-shaped osteoblasts that become flattened to the lower image border.
Non-active endosteal appostion is evident on the top of the image (black arrow) without prior resorption (modeling) as flat osteoblasts or lining cells
cover osteoid (mineralized bone = green, osteoid = red; Goldner-Masson, 400x). F–I) Osteoid and cellular indices determined by 2D
histomorphometry point to a low bone turnover situation at the time of biopsies 1, 2 and 4. Normal bone turnover, leading to an increase in osteoid
apposition and thus increasing osteoid surface and volume appeared only after 50 months of BP treatment and after the treatment was switched to
strontium ranelate. Osteoid indices did not indicate any signs of hyperosteoidosis considering the reference ranges reported by Lips et al. [73].
doi:10.1371/journal.pone.0023638.g004
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and number because indices of connectivity density, structure
model index and trabecular bone pattern factor were predomi-
nantly enhanced. The degree of mineralization was maintained
although strontium deposition occurred on the bone surface level.
No mineralization defects (e.g. entrapped osteoid) or accumulation
of osteoid were detected. The appearance of tunneling resorption
lacunae, the new formation of osteon-like entities and mini-
modeling of endosteal humps in trabecular structures reflected a
novel particularity after treatment switch accompanied by an
increase in cancellous bone mass.
The enhancement in bone volume fraction following SR
treatment, which was evaluated by micro-tomography, was not
equally represented by increases in trabecular thickness or
trabecular number. The characteristics of the trabecular architec-
ture changed to a partly disorganized and somewhat compact
network without separated trabeculae; thus, the number of
individual trabeculae decreased but the connectivity density
increased. The structure model index (SMI) and trabecular bone
pattern factor (TBPf) were both negative, which may indicate the
formation of very dense, plate-like structures or many concave
structures created by tunneling resorption [29,56]. The discovered
reorganization mechanism also raises the question of whether this
could eventually lead to an increase in ‘new’ trabeculae.
Compared to normal trabecular thickness values obtained from
histomorphometric studies [54,55], an unusual thickness of 300–
400 mm was measured for many plate-like structures. Many of
these thick trabeculae included newly formed osteon-like struc-
tures, which are characteristically found in the cortex around
Haversian canals [57]. mCT observations revealed that a majority
of these canals or tunnels create a complex, interconnected system
as can be seen in the cortex between Haversian and Volkmann
canals. The relevancy of its development in cancellous bone
remains uncertain. It can only be speculated whether this new
intratrabecular canal system that has developed outside of the
cortex maintains blood supply to the osteocyte network in the
inner regions of unusually thick trabeculae [58]. Inta-trabecular
osteons may act to ensure adequate diffusion of nutrients to, and
waste products from, osteocytes by limiting the maximum distance
between the osteocytes and the bone surface [59]. In particular,
thin nonmineralized pericellular zones between osteocytes and
their surrounding bone allow a strain-derived flow of interstitial
fluid over the osteocytes’ surfaces that is important for the
osteocytes’ health because it facilitates the exchange of nutrients
and waste products between the haversian channel and the
osteocyte network [60,61]. Although not investigated in this study,
a dramatic change in the cancellous structure from a plate-like to
rod-like shape with aging and osteoporosis has been reported and
results in a decrease in mechanical competence [62,63]. The
measured reversal of the bone structure due to changes in
treatment may therefore improve the bone’s elastic modulus [64].
There are several possible factors that may account for the
dramatic increase in bone volume. Because the trabecular
thickness only slightly increased by a mean of 0.03 mm, which
only explains about one third of the gain in bone volume, a
possible explanation was found in the reorganization pattern.
Endosteal appostion on the trabecular surfaces without prior
resorption (modeling) was found in the biopsy after SR treatment.
These small modeling sites, which are also known as mini-modeling
Figure 5. Bone mineral density distribution and microanalysis. A) Histology of the cancellous bone area after strontium ranelate treatment.
Intratrabecular cavities and thin osteoid seams are visible (mineralized bone = green, Goldner-Masson, 40x). B) Quantitative backscattered image of
the selected area in panel A. Intratrabecular resoption sites showed osteon-like structures (R). The gray level distribution reflects the mineralization
density, which varied between new and old bone. Newly formed osteon-like structures showed dark-gray pixels in comparison to older bright-gray
bone packets. C) Microanalysis mapping showed that increased strontium deposition (red dots) appeared predominantly around newly formed
osteon-like structures (R) as well as in modeling sites on endosteal surfaces (R). D) Combined EDX/mXRF microanalysis spectra demonstrated a
deposition of 1.63 Wt% strontium (peak) in the mineralized tissue after SR treatment.
doi:10.1371/journal.pone.0023638.g005
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[65,66], thicken and rearrange the remaining trabeculae to best
adapt to functional demands. Multiple long and deep, hook-like
resorption cavities, which are frequently seen and reported in renal
osteopathies (e.g. ROD type IIIb) [67], were observed. Similar
resorption sites were first described by Woods (1972) and later
quantified by Sato (1981) under conditions of osteoidosis and
increased PTH serum levels [68,69]. The cause was suspected to
be multifactorial, including maintenance of calcium homeostasis
through a compensatory increase in resorption depth in
osteomalacic situations and PTH-induced overstimulation of
osteoclasts. Low calcium or abnormal PTH serum levels were
not found in our patient but could have played a role in the early
stages of SR-induced bone formation that created a temporary
calcium deficit and a need for increased bone resorption. The SR
treatment stimulated bone turnover, which was demonstrated by
moderate serum bone markers (bAP, CTX), and indicated
increased bone formation (endosteal humps with osteoblast
coverage and newly formed bone packets with an accumulation
of strontium). An uncoupling with a pronounced suppression of
osteoclastic resorption was not present histologically or biochem-
ically after 12 months of SR administration. However, a complete
uncoupling was not expected because it is known that an
osteoclast-derived stimulus is required for normal bone remodeling
involving bone formation. In this connection, osteoclastic
resorption re-activated by strontium ranelate’s mode of action
may account not only for the improvement in bone mass and
structural integrity but also for the maintenance of calcium
metabolism.
Previous reports have shown that strontium is predominantly
incorporated into new, and to a lesser degree, old bone in a dose-
dependent matter without altering the degree of bone minerali-
zation [11,15,16]. Based on theoretical models, other groups
report that calcium substitution by strontium at the crystal level
and its higher attenuation of x-rays could account for up to 10% of
the total bone mineral density as measured by DXA, depending on
the time of SR administration [12,14,70]. Clinical BMD scores
acquired from the hip with DXA did not change significantly in
our patient. The only assumption the authors could make from
these results was that newly formed bone with a low mineral
content was not able to offset the deterioration of the trabecular
architecture in the femoral neck that may have irreversibly
progressed before SR treatment was initiated. mCT uses a similar
X-ray (fan beam) technique and is potentially influenced by the
degree of attenuation. The strontium content in the bone after 12
months of treatment in the investigated patient clearly rose
significantly to 1.63 Wt%. Despite the fact that we observed some
areas with an unusually high degree of mineralization (.1200 mg
HA/cm3), the average mean tissue density (mCT) after SR
administration did not change significantly. This finding might
be due to the fact that the tissue density in biopsy 4 (1133 mg HA/
cm3) was already high and had reached a maximum saturation
point. Therefore, tissue mineralization would not have a major
impact on bone mineral density measurements.
This study has several limitations. First, the heterogeneity of the
trabecular microstructure in different sites of the skeleton may have
an effect on the accuracy of the measured structural indices
[48,71,72]. Second, because more than one biopsy was obtained on
each side of the Ilium, there remains the possibility that a later
biopsy will overlap in parts with the location of a prior biopsy and
include regions of the Ilium that healed following the earlier biopsy.
Third, the study of five biopsies is limited to only one individual.
In this study, analyses of progressively obtained iliac crest bone
biopsies over six years of osteoporosis treatment highlight
remarkable changes in cancellous architecture, which are reinforced
by a switch from an antiresorptive agent to a dual action bone agent.
The clinical and microstructural information gained by an
unusually high number of bone biopsies demonstrated treatment-
associated responses in a novel case. These insights may support the
understanding of reorganization mechanisms due to alternating
osteoporosis treatments. Clinical bone markers showed that
strontium ranelate stimulated bone formation and simultaneously
bone resorption despite prior long-term antiresorptive treatment. In
this case, administration of strontium ranelate for one year led to
remarkable changes in trabecular structure with an impressive gain
in bone volume fraction at the iliac crest, which may contribute to
changes in bone quality.
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